FEV₁/FVC Ratio (Airflow Obstruction)
Interprets spirometry FEV₁/FVC ratio to classify airflow obstruction severity per GOLD criteria.
Score interpretation
FEV₁/FVC ≥ 0.70: No airflow obstruction. Pattern may be normal or restrictive.
→ If restrictive pattern (reduced FVC, normal ratio): consider ILD, chest wall disease. Refer for full lung function tests (TLC/DLCO).
Obstruction with FEV₁ ≥ 80%: GOLD 1 (Mild). Post-bronchodilator ratio < 0.70 required for COPD diagnosis.
→ SABA (as needed). Smoking cessation. Vaccinations.
Obstruction with FEV₁ 50–79%: GOLD 2 (Moderate).
→ LABA or LAMA. Consider combination. Pulmonary rehabilitation referral.
Obstruction with FEV₁ 30–49%: GOLD 3 (Severe).
→ Dual bronchodilation (LABA+LAMA). ICS if frequent exacerbations or eosinophils ≥300. Specialist review.
Obstruction with FEV₁ < 30%: GOLD 4 (Very Severe).
→ Triple therapy. Consider LTOT if PaO₂ < 7.3 kPa. Evaluate for lung transplant. Palliative care.
Interpretation bands for the FEV₁/FVC. Apply clinical judgement and local guidance.
References
- GOLD Global Strategy for COPD. 2024.
Related
Curated clinical cross-links plus same-class fallbacks.
- Azithromycin (COPD Exacerbation Prophylaxis) · Macrolide antibiotic (anti-inflammatory / prophylactic)
- Doxycycline (COPD Exacerbation / CAP) · Oral tetracycline antibiotic
- Co-amoxiclav 625mg (COPD Exacerbation / CAP) · Beta-lactam / Beta-lactamase inhibitor combination antibiotic
- Fluticasone Furoate / Vilanterol · ICS/LABA — Asthma / COPD
- Beclometasone / Formoterol · ICS/LABA — Asthma / COPD
- Fluticasone Furoate / Umeclidinium / Vilanterol · Triple Therapy ICS/LAMA/LABA — COPD
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.